Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANABNASDAQ:EDITNASDAQ:VIRNASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$23.17-0.9%$21.29$12.21▼$41.31$687.21M-0.26638,189 shs454,361 shsEDITEditas Medicine$2.22-5.5%$1.67$0.91▼$6.05$196.73M2.12.59 million shs3.06 million shsVIRVir Biotechnology$5.23+0.4%$5.30$4.32▼$14.45$720.22M1.241.38 million shs2.95 million shsXERSXeris Biopharma$4.51-1.5%$4.58$2.03▼$6.07$716.24M0.712.01 million shs3.13 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-0.94%-0.64%+11.34%+35.66%+1.22%EDITEditas Medicine-5.53%+12.69%+48.00%+69.47%-55.95%VIRVir Biotechnology+0.38%+0.19%+15.96%-24.53%-41.56%XERSXeris Biopharma-1.53%+3.68%-8.33%-22.38%+111.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio2.0269 of 5 stars3.40.00.00.03.51.70.6EDITEditas Medicine3.806 of 5 stars3.22.00.04.21.42.50.6VIRVir Biotechnology2.3498 of 5 stars3.41.00.00.00.63.31.3XERSXeris Biopharma4.2008 of 5 stars3.42.00.04.23.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$42.3882.89% UpsideEDITEditas Medicine 2.31Hold$4.70111.71% UpsideVIRVir Biotechnology 2.86Moderate Buy$32.86528.24% UpsideXERSXeris Biopharma 2.83Moderate Buy$6.2538.58% UpsideCurrent Analyst Ratings BreakdownLatest EDIT, XERS, VIR, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.005/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.005/9/2025XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$91.28M7.46N/AN/A$2.33 per share9.94EDITEditas Medicine$32.31M5.75N/AN/A$1.63 per share1.36VIRVir Biotechnology$74.21M9.74N/AN/A$8.35 per share0.63XERSXeris Biopharma$203.07M3.47N/AN/A($0.20) per share-22.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)EDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)VIRVir Biotechnology-$521.96M-$4.22N/AN/AN/A-2,769.04%-47.46%-39.33%7/30/2025 (Estimated)XERSXeris Biopharma-$54.84M-$0.30N/AN/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)Latest EDIT, XERS, VIR, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/8/2025Q1 2025XERSXeris Biopharma-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A8.258.25EDITEditas MedicineN/A3.083.08VIRVir BiotechnologyN/A6.796.79XERSXeris BiopharmaN/A1.721.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AEDITEditas Medicine71.90%VIRVir Biotechnology65.32%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%EDITEditas Medicine2.10%VIRVir Biotechnology16.00%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million19.54 millionOptionableEDITEditas Medicine23083.71 million81.96 millionOptionableVIRVir Biotechnology580138.24 million116.12 millionOptionableXERSXeris Biopharma290156.38 million146.27 millionOptionableEDIT, XERS, VIR, and ANAB HeadlinesRecent News About These CompaniesXeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term InvestingJune 18 at 10:17 AM | seekingalpha.comXeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying ActivityJune 18 at 1:11 AM | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying ActivityJune 17, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 SharesJune 17, 2025 | insidertrades.comKevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) StockJune 16, 2025 | marketbeat.comLeerink Partnrs Estimates Xeris Biopharma FY2025 EarningsJune 9, 2025 | marketbeat.comLeerink Partnrs Cuts Earnings Estimates for Xeris BiopharmaJune 6, 2025 | marketbeat.comXeris Biopharma touts ambitious growth plan, promising hypothyroidism drugJune 4, 2025 | chicagobusiness.comMackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 4, 2025 | marketbeat.comXeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor DayJune 3, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Shares Down 5.5% - Here's What HappenedJune 3, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from AnalystsJune 3, 2025 | marketbeat.comNuveen Asset Management LLC Acquires 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 1, 2025 | marketbeat.comMillennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 29, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 28, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street ZenMay 24, 2025 | marketbeat.comXeris Announces Details for Analyst & Investor DayMay 20, 2025 | businesswire.comXeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in NowMay 12, 2025 | msn.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comXeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...May 9, 2025 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAlphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden Driver3 Tech Stocks You Can't Miss in This Market CycleBy Gabriel Osorio-Mazilli | June 17, 2025View 3 Tech Stocks You Can't Miss in This Market CycleEDIT, XERS, VIR, and ANAB Company DescriptionsAnaptysBio NASDAQ:ANAB$23.17 -0.22 (-0.94%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$23.16 -0.01 (-0.02%) As of 06/20/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Editas Medicine NASDAQ:EDIT$2.22 -0.13 (-5.53%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.19 -0.03 (-1.13%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Vir Biotechnology NASDAQ:VIR$5.23 +0.02 (+0.38%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.20 -0.03 (-0.48%) As of 06/20/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Xeris Biopharma NASDAQ:XERS$4.51 -0.07 (-1.53%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.39 -0.12 (-2.55%) As of 06/20/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
